The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma
Relapsed and refractory (R/R) multiple myeloma (MM) constitutes a specific and unmet medical need. Median survival ranges from as little as 6 to 9 months, and responses to treatment are characteristically short. In patients with R/R MM after therapy of bortezomib and/or immunomodulators a bendamusti...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2015-10-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/149 |
| _version_ | 1797855530911268864 |
|---|---|
| author | S. V. Voloshin S. S. Bessmeltsev T. P. Zagoskina N. V. Medvedeva K. D. Kaplanov E. V. Karyagina A. D. Garifullin A. Yu. Kuvshinov L. V. Stelmashenko K. M. Abdulkadyrov |
| author_facet | S. V. Voloshin S. S. Bessmeltsev T. P. Zagoskina N. V. Medvedeva K. D. Kaplanov E. V. Karyagina A. D. Garifullin A. Yu. Kuvshinov L. V. Stelmashenko K. M. Abdulkadyrov |
| author_sort | S. V. Voloshin |
| collection | DOAJ |
| description | Relapsed and refractory (R/R) multiple myeloma (MM) constitutes a specific and unmet medical need. Median survival ranges from as little as 6 to 9 months, and responses to treatment are characteristically short. In patients with R/R MM after therapy of bortezomib and/or immunomodulators a bendamustine-based treatment can be used as “salvage”.In this retrospective analysis we have identified 32 patients with R/R MM by means of case research, have been bendamustine-based treated at Hematological Clinics of Russian Federation since 2011. Median age was 67 (43–81) years, the female/male ratio was 2.5:1. After in median 2 (1–7) lines of prior therapy patients received in median 3 (1–9) cycles of bendamustine-based therapy. Bendamustine dosage was 70–120 mg/m2 /day on 2 days of each 28-day cycle until progressive disease or intolerability. Overall rate response was 56.2 %: 21.9 % partial response, stable disease 34.4 %. Median time to progression was 5.3 (0.8–18.0) months and median overall survival was 25.4 (0.8–47.1) months. Hematologic toxicity was in 53.2 % of patients. |
| first_indexed | 2024-04-09T20:25:15Z |
| format | Article |
| id | doaj.art-3a9bc84bcc124ee88a5b7e2d94b39c1b |
| institution | Directory Open Access Journal |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| last_indexed | 2024-04-09T20:25:15Z |
| publishDate | 2015-10-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj.art-3a9bc84bcc124ee88a5b7e2d94b39c1b2023-03-30T20:15:11ZrusABV-pressОнкогематология1818-83462413-40232015-10-01103101710.17650/1818-8346-2015-10-3-10-17163The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myelomaS. V. Voloshin0S. S. Bessmeltsev1T. P. Zagoskina2N. V. Medvedeva3K. D. Kaplanov4E. V. Karyagina5A. D. Garifullin6A. Yu. Kuvshinov7L. V. Stelmashenko8K. M. Abdulkadyrov9Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological AgencyRussian Research Institute of Hematology and Transfusiology, Federal Medical and Biological AgencyKirov Institute of Hematology and Transfusiology, Federal Medical and Biological AgencyCity Clinical Hospital № 31Volgograd Regional Clinical Oncology Dispensary № 1City Hospital № 15Russian Research Institute of Hematology and Transfusiology, Federal Medical and Biological AgencyRussian Research Institute of Hematology and Transfusiology, Federal Medical and Biological AgencyRussian Research Institute of Hematology and Transfusiology, Federal Medical and Biological AgencyRussian Research Institute of Hematology and Transfusiology, Federal Medical and Biological AgencyRelapsed and refractory (R/R) multiple myeloma (MM) constitutes a specific and unmet medical need. Median survival ranges from as little as 6 to 9 months, and responses to treatment are characteristically short. In patients with R/R MM after therapy of bortezomib and/or immunomodulators a bendamustine-based treatment can be used as “salvage”.In this retrospective analysis we have identified 32 patients with R/R MM by means of case research, have been bendamustine-based treated at Hematological Clinics of Russian Federation since 2011. Median age was 67 (43–81) years, the female/male ratio was 2.5:1. After in median 2 (1–7) lines of prior therapy patients received in median 3 (1–9) cycles of bendamustine-based therapy. Bendamustine dosage was 70–120 mg/m2 /day on 2 days of each 28-day cycle until progressive disease or intolerability. Overall rate response was 56.2 %: 21.9 % partial response, stable disease 34.4 %. Median time to progression was 5.3 (0.8–18.0) months and median overall survival was 25.4 (0.8–47.1) months. Hematologic toxicity was in 53.2 % of patients.https://oncohematology.abvpress.ru/ongm/article/view/149multiple myelomabendamustinebortezomiblenalidomidestem cells transplantationgenetic abnormalities |
| spellingShingle | S. V. Voloshin S. S. Bessmeltsev T. P. Zagoskina N. V. Medvedeva K. D. Kaplanov E. V. Karyagina A. D. Garifullin A. Yu. Kuvshinov L. V. Stelmashenko K. M. Abdulkadyrov The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma Онкогематология multiple myeloma bendamustine bortezomib lenalidomide stem cells transplantation genetic abnormalities |
| title | The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma |
| title_full | The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma |
| title_fullStr | The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma |
| title_full_unstemmed | The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma |
| title_short | The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma |
| title_sort | multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma |
| topic | multiple myeloma bendamustine bortezomib lenalidomide stem cells transplantation genetic abnormalities |
| url | https://oncohematology.abvpress.ru/ongm/article/view/149 |
| work_keys_str_mv | AT svvoloshin themulticenterexperiencewithbendamustineinthetreatmentofrelapsedandrefractorymultiplemyeloma AT ssbessmeltsev themulticenterexperiencewithbendamustineinthetreatmentofrelapsedandrefractorymultiplemyeloma AT tpzagoskina themulticenterexperiencewithbendamustineinthetreatmentofrelapsedandrefractorymultiplemyeloma AT nvmedvedeva themulticenterexperiencewithbendamustineinthetreatmentofrelapsedandrefractorymultiplemyeloma AT kdkaplanov themulticenterexperiencewithbendamustineinthetreatmentofrelapsedandrefractorymultiplemyeloma AT evkaryagina themulticenterexperiencewithbendamustineinthetreatmentofrelapsedandrefractorymultiplemyeloma AT adgarifullin themulticenterexperiencewithbendamustineinthetreatmentofrelapsedandrefractorymultiplemyeloma AT ayukuvshinov themulticenterexperiencewithbendamustineinthetreatmentofrelapsedandrefractorymultiplemyeloma AT lvstelmashenko themulticenterexperiencewithbendamustineinthetreatmentofrelapsedandrefractorymultiplemyeloma AT kmabdulkadyrov themulticenterexperiencewithbendamustineinthetreatmentofrelapsedandrefractorymultiplemyeloma AT svvoloshin multicenterexperiencewithbendamustineinthetreatmentofrelapsedandrefractorymultiplemyeloma AT ssbessmeltsev multicenterexperiencewithbendamustineinthetreatmentofrelapsedandrefractorymultiplemyeloma AT tpzagoskina multicenterexperiencewithbendamustineinthetreatmentofrelapsedandrefractorymultiplemyeloma AT nvmedvedeva multicenterexperiencewithbendamustineinthetreatmentofrelapsedandrefractorymultiplemyeloma AT kdkaplanov multicenterexperiencewithbendamustineinthetreatmentofrelapsedandrefractorymultiplemyeloma AT evkaryagina multicenterexperiencewithbendamustineinthetreatmentofrelapsedandrefractorymultiplemyeloma AT adgarifullin multicenterexperiencewithbendamustineinthetreatmentofrelapsedandrefractorymultiplemyeloma AT ayukuvshinov multicenterexperiencewithbendamustineinthetreatmentofrelapsedandrefractorymultiplemyeloma AT lvstelmashenko multicenterexperiencewithbendamustineinthetreatmentofrelapsedandrefractorymultiplemyeloma AT kmabdulkadyrov multicenterexperiencewithbendamustineinthetreatmentofrelapsedandrefractorymultiplemyeloma |